IMU’s discovery engine maps the immune system in unprecedented detail and scale to deliver unique, systems-level immune insights.
Use our platform today to measure +2,000 discrete cell subset capturing systems-level immune profiles, to power in-depth disease modeling, drug development, patient monitoring, and translational research
IMU Biosciences joins ground-breaking UK research consortium investigating patient response to cancer immunotherapies
London, UK, 7 October 2024
IMU Biosciences joins NVIDIA Inception Programme to Accelerate AI-Driven Precision Medicine
London, UK, 3 October 2024
IMU Biosciences expands leadership team with appointment of industry experts Dr. John Baker as Chief Executive Officer and Dr. Jason Brown as Chief Business Officer
London, UK, 17 September 2024
IP10 levels refine severity prognostication in COVID-19 and implicate causes of clinical deterioration: lessons for pandemic preparedness
Cardinnate
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
London, UK, 24 January 2024
A dynamic COVID-19 immune signature includes associations with poor prognosis
Nature Medicine
IMU Biosciences secures £11.5 million in Series A funding to revolutionise immune powered precision medicine
London, UK, 24 January 2024 — IMU Biosciences (or “the Company”), a techbio company revolutionising immune powered precision medicine, today announces the close of a £11.5 million Series A financing round. The round was led by European tech VC Molten Ventures and included LifeX Ventures and other individuals.